Combipres — Competitive Intelligence Brief

Combipres (Chlortalidone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazide-like Diuretic. Area: Cardiovascular.

marketed Thiazide-like Diuretic Carbonic anhydrase 7 Cardiovascular Small molecule

Target snapshot

Combipres (Chlortalidone) — University Hospital Birmingham.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Combipres TARGET	Chlortalidone	University Hospital Birmingham	marketed	Thiazide-like Diuretic	Carbonic anhydrase 7	1960-01-01
Lozol	INDAPAMIDE		marketed	Thiazide-like Diuretic [EPC]	Carbonic anhydrase 7	1983-01-01
Catechin	CIANIDANOL		marketed		Carbonic anhydrase 7	1977-01-01
Zaroxolyn	METOLAZONE	I3 Pharms	marketed	Thiazide-like Diuretic [EPC]	Carbonic anhydrase 7	1973-01-01
CHLORTHALIDONE	CHLORTHALIDONE		marketed	Thiazide-like Diuretic [EPC]	Na+/Cl− cotransporter	1960-01-01
Metolazone concurrently with furosemide	Metolazone concurrently with furosemide	University of Maryland, Baltimore	marketed	Thiazide-like diuretic and loop diuretic combination	Sodium-chloride cotransporter (NCC) and sodium-potassium-chloride cotransporter (NKCC2)
Metolazone Tablets	Metolazone Tablets	NHS Greater Glasgow and Clyde	marketed	Thiazide-like diuretic	Na-Cl cotransporter (NCC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2028-03-26 — Combipres · 9066936 · US
• 2030-02-04 — Combipres · 9169238 · US
• 2031-07-01 — Combipres · 9387249 · US

Sponsor landscape (Thiazide-like Diuretic class)

1. University Hospital Birmingham · 1 drug in this class